Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation

Liver Transpl. 2016 Sep;22(9):1295-300. doi: 10.1002/lt.24495.

Authors

Affiliations

¹ Multi Organ Transplant Program, University Health Network, University of Toronto, Ontario, Canada.
² Departments of Pathology, University Health Network, University of Toronto, Ontario, Canada.
³ Radiology, University Health Network, University of Toronto, Ontario, Canada.

PMID: 27314458
DOI: 10.1002/lt.24495

No abstract available

Publication types

Letter

MeSH terms

Adult
Biopsy
Caloric Restriction / adverse effects
Caloric Restriction / methods*
Donor Selection / methods
End Stage Liver Disease / mortality
End Stage Liver Disease / surgery*
Fatty Liver / diet therapy*
Fatty Liver / pathology
Female
Hepatectomy / adverse effects
Hepatectomy / mortality
Humans
Liver / pathology
Liver / surgery
Liver Transplantation / adverse effects
Liver Transplantation / methods*
Living Donors / statistics & numerical data
Male
Middle Aged
Patient Selection
Postoperative Complications / epidemiology
Retrospective Studies
Transplant Recipients / statistics & numerical data
Treatment Outcome
Weight Loss